Want to see IN:DCAL full AI Analyst Report?
DCAL Stock Chart & Stats
₹255.15
-₹14.00(-4.80%)
At close: 4:00 PM EST
₹255.15
-₹14.00(-4.80%)
Day’s Range― - ―
52-Week Range₹129.00 - ₹321.15
Previous CloseN/A
Volume578.20K
Average Volume (3M)13.55K
Market Cap
₹27.48B
Enterprise Value₹47.16B
Total Cash (Recent Filing)₹5.32B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)28.2
Beta1.20
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.65
Shares Outstanding156,783,100
10 Day Avg. Volume9,637
30 Day Avg. Volume13,551
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.30
Price to Sales (P/S)0.69
P/FCF Ratio26.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
CDMO/CRAMS Business ModelA core CDMO/CRAMS model provides durable, contract-driven revenue streams and exposure to long product development cycles. Serving drug developers and specialty-chemical buyers supports recurring project work, scale advantages, and stickiness versus one-off commodity sellers, supporting long-term cash generation.
Consistent Operating Cash FlowReliable operating cash flow underpins the company's ability to fund working capital, service debt and invest in capacity without depending solely on volatile accounting profits. This resilience improves financial flexibility and supports longer-term investment in scale and capability buildouts.
Revenue Re-accelerationA re-acceleration in top-line growth signals improving demand for services and products and helps absorb fixed costs. Sustained revenue expansion increases potential for margin recovery and returns to scale, providing a structurally stronger base for future profitability improvements if maintained.
Bears Say
Volatile Profitability And MarginsLarge swings in profitability and margins weaken predictability of earnings and make capital allocation harder. For a CDMO, inconsistent margins often reflect project timing, pricing variability and mix risk, which can constrain ability to sustainably reinvest or deliver steady returns to stakeholders.
Rising Total DebtAn increasing debt load raises fixed financial obligations and reduces optionality for growth investments or cushioning during downcycles. Given uneven profits and returns, higher leverage heightens refinancing and interest-rate risks and can limit strategic flexibility over the medium term.
Uneven Free Cash Flow ConversionSharp swings in free cash flow constrain the firm's ability to consistently fund capital expenditure, repay debt or return capital. While recent recovery to positive FCF is constructive, the historical inconsistency increases reliance on external funding in weak years and complicates long-term planning.
Dishman Carbogen Amcis Ltd. News
DCAL FAQ
What was Dishman Carbogen Amcis Ltd.’s price range in the past 12 months?
Dishman Carbogen Amcis Ltd. lowest stock price was ₹129.00 and its highest was ₹321.15 in the past 12 months.
What is Dishman Carbogen Amcis Ltd.’s market cap?
Dishman Carbogen Amcis Ltd.’s market cap is ₹27.48B.
When is Dishman Carbogen Amcis Ltd.’s upcoming earnings report date?
Dishman Carbogen Amcis Ltd.’s upcoming earnings report date is Aug 12, 2026 which is in 41 days.
How were Dishman Carbogen Amcis Ltd.’s earnings last quarter?
Dishman Carbogen Amcis Ltd. released its earnings results on May 19, 2026. The company reported ₹1.39 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.39.
Is Dishman Carbogen Amcis Ltd. overvalued?
According to Wall Street analysts Dishman Carbogen Amcis Ltd.’s price is currently Overvalued.
Does Dishman Carbogen Amcis Ltd. pay dividends?
Dishman Carbogen Amcis Ltd. pays a Annually dividend of ₹0.2 which represents an annual dividend yield of N/A. See more information on Dishman Carbogen Amcis Ltd. dividends here
What is Dishman Carbogen Amcis Ltd.’s EPS estimate?
Dishman Carbogen Amcis Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Dishman Carbogen Amcis Ltd. have?
Dishman Carbogen Amcis Ltd. has 156,783,100 shares outstanding.
What happened to Dishman Carbogen Amcis Ltd.’s price movement after its last earnings report?
Dishman Carbogen Amcis Ltd. reported an EPS of ₹1.39 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.399%.
Which hedge fund is a major shareholder of Dishman Carbogen Amcis Ltd.?
Currently, no hedge funds are holding shares in IN:DCAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Dishman Carbogen Amcis Ltd.
Established in 1983 and headquartered in Ahmedabad, India, Dishman Carbogen Amcis Limited provides specialized contract research and manufacturing solutions to the worldwide pharmaceutical sector. The company operates through two main business segments: Contract Research and Manufacturing Services (CR&MS), and Marketable Molecules. Beyond its core services, it manufactures and distributes an extensive portfolio of products, including bulk drugs, chemical intermediates, various phase transfer catalysts, quaternary ammonium compounds, phosphoranes, wittig reagents, vitamin D derivatives, and fine chemicals. Additionally, its offerings encompass personal care products like hand and body washes, sanitizers, and antiseptics, as well as a range of pharmaceutical and cosmetic formulations, including generic and highly potent active pharmaceutical ingredients. Dishman Carbogen Amcis Limited is a subsidiary of Adimans Technologies LLP.
Technical Analysis
Biocon Limited
―
Concord Biotech Ltd.
―
Jubilant Ingrevia Ltd.
―
Panacea Biotec Limited
―
Syngene International Ltd.
―